MCT4 is an important determinant for the growth of highly glycolytic and aggressive malignancies by Unsal-Kacmaz, Kezi et al.
ORAL PRESENTATION Open Access
MCT4 is an important determinant for the growth
of highly glycolytic and aggressive malignancies
Kezi Unsal-Kacmaz
*, Shoba Ragunathan, Jennifer Shan, Bing Guo, Xiaoli Wang, Diane Tkach, Judy Lucas,
Anke Klippel
From Metabolism, diet and disease
Washington, DC, USA. 29-31 May 2012
Constitutive upregulation of glycolysis is likely to be an
adaptation to hypoxia that develops as premalignant lesions
grow progressively distant from their blood supply.
Increased lactic acid production caused by the upregulation
of glycolysis results in microenvironmental acidosis. Cell
populations that emerge from this adaptation have a
powerful growth advantage, as they alter their environment
through increased glycolysis in a way that is toxic to other
phenotypes, but harmless to themselves or their re-
programmed stromal environment. Our goal is to elucidate
the molecular basis for this aberrant behavior, and harness
that knowledge towards the development of effective thera-
peutic strategies against malignant tumors. Here we
describe in vitro/in vivo functional analysis of MCT1,
MCT4 and CD147 in three different cell contexts, where
MCT1 and MCT4 are expressed either alone or together
and confer differential growth advantages under hypoxic or
normoxic conditions. We show the selective enrichment of
CD147 and MCT4 in highly tumorigenic CD133/CD44
positive cells from colon cancer patient-derived-xenografts.
Our findings indicate that MCT4 is an important
determinant for the growth of highly glycolytic and
aggressive malignancies, which so far has not been
explored as a target for therapeutic purposes and may
provide a unique avenue for anticancer therapy. We will
provide in-vitro and in-vivo evidence for tumor contexts,
where the selective inhibition of MCT4 is sufficient as
well as contexts, for which the combined inhibition of
MCT1 and MCT4 is required for providing a therapeutic
benefit.
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